There are several pan-PIM kinase inhibitors in development for cancer indications, but startup Mysthera Therapeutics AG hopes to become the first biotech company to develop them in the autoimmune diseases space, having secured $3.5 million in seed capital from founding investor Forty51 Ventures.
Everest Medicines Ltd. is in-licensing Kezar Life Sciences Inc.’s phase II autoimmune disease candidate, zetomipzomib in a deal worth $132 million for greater China, South Korea and southeast Asia rights. Kezar’s lead molecule zetomipzomib (KZR-616) is a first-in-class, selective immunoproteasome inhibitor with broad therapeutic potential across multiple autoimmune diseases.
Everest Medicines Ltd. is in-licensing Kezar Life Sciences Inc.’s phase II autoimmune disease candidate, zetomipzomib in a deal worth $132 million for greater China, South Korea and southeast Asia rights. Kezar’s lead molecule zetomipzomib (KZR-616) is a first-in-class, selective immunoproteasome inhibitor with broad therapeutic potential across multiple autoimmune diseases.
Wuhan LL Science & Technology Development Co. Ltd. has synthesized mannan-binding lectin serine protease 2 (MASP2) inhibitors reported to be useful for the treatment of lupus nephritis and IgA nephropathy, among others.
Artiva Biotherapeutics Inc. has received FDA clearance of its IND application for Allonk (AB-101), to be used in combination with rituximab for treatment of systemic lupus erythematosus (SLE) in patients with active lupus nephritis.
Gri Bio Inc. reported data on its type 2 natural killer T (NKT) cell activator GRI-0803 at the Autoimmunity Conference hosted by FASEB earlier in August. The company is developing GRI-0803 in autoimmune diseases, with an initial focus of systemic lupus erythematosus (SLE).
Aria Pharmaceuticals Inc. has described C-C chemokine receptor type 2 (CCR2; MCP-1-R) modulators reported to be useful for the treatment of systemic lupus erythematosus (SLE) and lupus nephritis.
Maze Therapeutics has patented apolipoprotein L1 (APOL1) inhibitors reported to be useful for the treatment of chronic kidney disease, focal segmental glomerulosclerosis, HIV-associated nephropathy, lupus nephritis and sepsis.
